Introduction
Following the development of multifarious imaging technologies and improvements in relation to health education, the worldwide incidence of thyroid cancer has rapidly increased over the past number of decades [1] [2] [3] . Papillary thyroid cancer (PTC), which initially develops in follicular cells, is the most common differentiated thyroid cancer, representing 80-90% of all thyroid cancers. The BRAF V600E mutation is one of the most prevalent somatic genetic events during PTC. This mutation is associated with lymph node metastasis, distant metastasis, extrathyroidal extension, and a high risk of recurrence. Thus, BRAF V600E has been suggested as a potential prognostic factor in PTC patients [4] [5] [6] [7] . However, the association between the BRAF V600E mutation and negative prognostic indicators such as lymphovascular invasion, extranodal extension, and distant metastasis is not significant after adjusting for clinical and histopathological features [8, 9] . Sex has also been shown to affect PTC incidence, with the rate of PTC being nearly 3 times higher in females than in males [10] .
There has been much conjecture regarding the role of the BRAF V600E mutation in PTC; however, recent evidence suggests a role for the mutations in membrane ion transport systems. The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates active iodide transport into the thyroid gland and several extrathyroidal tissues. A previous study indicated that the BRAF V600E mutation represses NIS transcription while also impairing NIS localization to the plasma membrane [11] . Transforming growth factor beta (TGF-β) regulates many physiological processes during development, wound healing, and tissue homoeostasis [12, 13] . This cytokine can function as both a tumor suppressor and a tumor promoter depending on how it is deployed [14] . In normal thyroid epithelial cells, TGF-β represses NIS expression [15] . However, overexpression of TGF-β has been shown to occur
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Summary Background: Papillary thyroid cancer (PTC) is the most common differentiated thyroid cancer and is responsible for 80-90% of thyroid cancer cases. Despite typically excellent prognoses, these subclinical low-risk cancers are often treated aggressively by surgical thyroidectomy. Consequently, the objective of this study was to generate a prognostic matrix to be used prior to PTC intervention. Methods: In this study, 80 PTC patients were assessed. Following adjustment for sex, logistic regression analysis showed that BRAF V600E mutation, transforming growth factor beta (TGF-) expression, age, and tumor size are risk factors that can affect tumor clinical stage (p < 0.05). Based on the results of this analysis, we generated a matrix that incorporated 4 variables: patient age, tumor size, BRAF V600E mutation, and TGF-expression. Results: We observed that the corresponding area under curve was as high as 0.91. The sensitivity and specificity of the model were 94.74 and 83.61%, respectively. These values are significantly higher than those generated from single indexes. Conclusion: As a result of this analysis, it is hoped that the resultant matrix can be utilized during clinical diagnosis and treatment prior to thyroid nodule surgery.
in the invasive front of human thyroid malignancies [16, 17] , whereas NIS is preferentially expressed in the central regions of tumors, suggesting that this negative correlative effect between TGF-β and NIS occurs locally inside the tumor [18] . Nonetheless, the exact relationship between the BRAF V600E mutation and TGF-β remains to be elucidated. In this analysis, we will discuss the prognostic value of the BRAF V600E mutation and TGF-β overexpression in relation to the clinical diagnosis and treatment of PTC.
Patients and Methods
Tumor Samples A total of 80 patients who underwent initial surgery for PTC (mean and median age: 45.65 and 47 years, respectively; female/male ratio: 61/19) from March to September 2014 were included in this study. All of the PTC tumor specimens were immediately frozen in liquid nitrogen and stored at -80 ° C prior to immunohistochemistry and expression analyses. None of the patients recruited as part of this study had a history of radiation exposure. The study was approved by the Medical Research Ethics Committee of Qingdao University and thus meets the standards of the Declaration of Helsinki. All of the patients were informed about the study and signed an informed consent form prior to the collection of tumor samples. All of the information pertaining to the patients remained confidential.
Histology
Histological diagnosis and description of variations pertaining to each tumor were performed and recorded according to the histopathological typing of the World Health Organization. Clinical and pathological staging were carried out according to the tumor-node-metastasis (TNM) classification system of the American Joint Committee on Cancer (AJCC) [19] . Stages I and II refer to patients who are younger than 45 years of age. These stages also refer to patients older than 45 years of age with a maximum tumor diameter of 4 cm and no regional lymph node metastasis or distant metastasis. Stages III and IV refer to patients with a maximum tumor diameter of > 4 cm, or with tumors that have developed beyond the thyroid envelope. The latter stages (III and IV) also refer to patients with lymph node metastasis.
Immunohistochemical Detection
Thyroid tissue sections (5 mm) obtained from 80 patients with PTC were studied using a catalyzed signal amplification protocol. All slides were subjected to antigen retrieval. The endogenous peroxide activity was blocked with 5% H 2 O 2 for 15 min. Slides were incubated for 1 h with human anti-TGFβ1 antibody (1/50), and anti-hNIS (1/1,000) diluted in serum-free protein block. The slides were subsequently blocked with avidin and biotin for 20 min each. Next, they were incubated with streptavidin peroxidase for 10 min and DAB substrate chromogen for 5 min. Peroxidase activity was observed as a brown product and detected using diaminobenzidene-hydrogen peroxide. 2 independent pathologists who were blinded to the BRAF mutation status of the tumors interpreted and graded the staining. Immunoreactivity was characterized as follows: cells that were not colored were deemed negative (-), cells that were weakly positive or exhibited scattered local coloring were scored +, cells that were moderately positive were scored ++, and cells that were strongly positive were scored +++.
RNA Extraction and Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from 30-100 mg of tissue using a commercial kit based on the guanidinium isothiocyanate method (RNAzol B, Tel-Test, Friendswood, TX, USA). First-strand cDNA synthesis was performed using 1 μg of each RNA sample and 1 μl of random hexamers according to the manufacturer's protocol (Promega Corp., Madison, WI, USA). The final reaction mixture, containing 20 μl, was incubated for 50 min at 42 ° C.
PCR Amplification and Sequence Analysis
cDNA was used as the template for the amplification of the BRAF gene (exon 15). Sequencing of the BRAF gene was performed using PCR products that were purified using a commercial kit (QIAquick PCR Purification Kit, Qiagen, Hilden, Germany). The resultant amplicons were sequenced using an automated system employing fluorescent dye terminators (ABI Prism 310, PerkinElmer, Foster City, CA, USA). The primer sequences for BRAF have been reported previously [20] . Amplifications were carried out using 2 μg of extracted DNA in a 25-μl PCR mixture containing 12.5 μl MasterAmp 2× PCR premix A (Epicentre, Madison, WI, USA), 5 μmol/l of each primer, and 7.5 μl of RNasefree H 2 O (Invitrogen, Carlsbad, CA, USA). Initial denaturation at 95 ° C for 1 min was followed by 35 cycles comprising 15 s at 95 ° C, 15 s at 55 ° C, and 30 s at 72 ° C, and a final 7-min extension step at 72 ° C. The specificity and integrity of the PCR products were confirmed by visualization of single PCR product bands with expected molecular weights on a 1.2% agarose gel. BRAF mutations were identified by single stranded conformation polymorphism, and results were confirmed by means of sequence analysis.
Quantitative Analysis of mRNA Expression by Real-Time RT-PCR
To perform quantitative RT-PCR, we used the RealTime Sequence Detection System 7700 (PE Applied Biosystems, Foster City, CA, USA). The primers and probes, which were specific for analyzing the genes including GAPDH, NIS, and TGFβ-1, were purchased from Applied Biosystems, Monza, Italy (PDAR and Assay-on Demand Gene Expression). Samples omitting either reverse transcriptase or cDNA were included in each run as controls for potential laboratory and/or assay contamination. Each sample was assayed in triplicate according to the conditions recommended by Applied Biosystems; 10 ng of cDNA were added to a mixture of 1× Universal Master Mix, 900 nM of each primer, and 200 nM of probe, in a final volume of 20 μl. The reaction mixtures were incubated for 2 min at 50 ° C, denatured for 10 min at 95 ° C, and subjected to 40 cycles of a 2-step PCR consisting of a 15 s denaturation step at 95 ° C and 1 min annealing/extension at 60 ° C. mRNA gene expression was assessed using the Ct method (Ct = Ct (analyzed gene)-Ct (GAPDH, ubiquitous referral gene), where Ct represents the threshold cycle for the quantitative real-time RT-PCR.
Statistical Analysis of the Results
Correlations between BRAF
V600E and clinicopathological parameters were analyzed in all 80 patients unless otherwise indicated. Results are presented as means ± standard deviation (SD) or as percentages, as appropriate. We used the t-test to compare continuous variables and the χ 2 test to determine p values in contingency tables. Quantitative PCR results are expressed as means ± standard error (SE), and differences were analyzed using the Mann-Whitney U test. Logistic regression analysis was used to examine the independent significance of certain parameters. The area under the receiver operating characteristics (ROC) curve (AUC) was used as an accuracy index to evaluate the diagnostic performance of the individual markers and the panel. p < 0.05 was considered statistically significant. Clinical data were stored and analyzed using SPSS software (IBM Corp., Armonk, NY, USA). MedCalc (version 10.4.7.0; MedCalc, Mariakerke, Belgium) software was used to perform the ROC and regression analyses. The predictive panel was validated using the open source package 'pROC' for R and S-PLUS [21] . 
Results
BRAF
Relationship between Expression of NIS mRNA, TGF-β mRNA, and Clinicopathological Variables
The real-time PCR products were quantitated according to the reaction curves. ANOVA was used to analyze the relationships between NIS mRNA expression, TGF-β mRNA expression, the BRAF mutation, and clinicopathological variables. There was no significant correlation between NIS mRNA expression and BRAF V600E mutation, sex, age (< 45 or 45 years), size (< 1 or 1 cm), lymph node metastases, or extrathyroidal extension. Similarly, no significant relationship was observed between TGF-β mRNA expression and BRAF V600E mutation, sex, age, lymph node metastases, or extrathyroidal extension. In contrast, expression of TGF-β mRNA in PTC tumors that were greater than 1 cm in diameter was lower compared with PTC tumors that were smaller than 1 cm in diameter (p < 0.05) ( fig. 1 ).
NIS and TGF-β Immunohistochemistry
We observed that NIS protein was expressed in almost all of the PTC patients (except for 3 cases) that were studied. This analysis revealed that NIS was localized in the membrane (n = 15), the cytoplasm (n = 6), or both (n = 56) ( fig. 2 ). For each sample, the percentage of NIS-positive and NIS-negative cells was calculated, and an arbitrary score indicating the degree of positivity was also applied (from the lowest (+) to the highest (+++)). The degree of NIS expression was significantly lower in PTCs harboring the BRAF V600E mutation than in negative cases (p = 0.002) (table 2).
Relatively increased TGF-β expression levels were observed in metastatic lymph nodes and the cytoplasm of most PTC cells ( fig. 3 ). There was no significant correlation between TGF-β ex- As part of this analysis, we also monitored the expression of NIS and TGF-β in the tissues surrounding the tumors. NIS expression in the surrounding tissues was comparable to that inside the tumor; however, NIS predominantly localized to cell membranes in the surrounding tissues. TGF-β expression was significantly weaker in surrounding tissues than inside the tumor; expression in the surrounding tissues was predominantly localized to the cytoplasm.
Establishing the Predictive Panel in a Clinical Setting
After adjusting for sex, logistic regression analysis showed that BRAF gene mutation, elevated expression of TGF-β, age ( 45 years), and tumor size (> 1 cm) were risk factors for tumor clinical stage (p < 0.05) (table 4). The diagnostic performance of using each of these individual variables and that of using all 4 variables were compared. We next assessed the diagnostic performance of the newly established combined panel using a ROC analysis. A total of 2,000 stratified bootstrap replicates [21] were utilized for this analysis, and the corresponding AUC was 0.910 (sensitivity = 94.74%; specificity = 83.61%) (table 5). The combined model performed significantly better than the single-variable models that assessed factors including BRAF V600E mutation or elevated expression of TGF-β (p < 0.05).
Discussion
The rapid increase in the number of newly detected cases of thyroid cancer, especially low-risk PTC, is due to the development of imaging technologies that permit subclinical disease detection [22] . However, despite the fact that individuals with small localized PTC display an excellent prognosis, these subclinical low-risk cancers are often treated aggressively. Identification of the cause of the disease is imperative when choosing the appropriate treatment regimen. The BRAF V600E mutation in the MAPK pathway has been studied as a prognostic molecular marker for aggressive clinicopathological outcomes. Previous reports have indicated that the incidence of the BRAF mutation is 29-83% [23] [24] [25] ; our study revealed that the BRAF V600E mutation was present in 57.5% of PTC patients. A recent meta-analysis of 2,470 patients with PTC found that this mutation was associated with an increased risk of tumor recurrence, lymph node metastasis, extrathyroidal extension, and advanced-stage thyroid cancer [26] . In a large retrospective multicenter study of 1,890 patients [27] , the BRAF mutation was associated with significantly increased cancer-related mortality; the median follow-up for these cases was 33 months [28] . In our small study of 80 cases, the BRAF V600E mutation correlated with sex, node metastases, and extrathyroidal extension (p < 0.05). However, we did not observe any significant relationship between the BRAF mutation and age, size, multicentricity, or advanced AJCC stage (p > 0.05). Indeed, these findings correlate with an analysis by Huang et al. [29] where the BRAF V600E mutation was not significantly associated with patient age, multicentric disease, and tumor stage. Furthermore, recent large retrospective cohorts found no association between the presence of BRAF mutations and tumor multicentricity, lymph vascular invasion, extranodal extension, central neck involvement, advanced stage (III-IV) occurrence, distant metastasis, or cause-specific survival in PTC [9, 10] . Furthermore, the prognostic value of the BRAF V600E mutation for lowrisk thyroid cancer was observed to decline progressively [27] .
NIS has been shown to participate in the transportation of iodine in thyroid cells. It has previously been suggested that BRAF V600E is a new prognostic factor for PTC, and mutation occurrence correlates with a high risk of recurrence and less differentiated tumors. In our study, NIS expression was significantly lower in PTCs harboring the BRAF V600E mutation than in BRAF V600E -negative cases (p = 0.002). Furthermore, localization of NIS in the cytoplasm was more obvious in BRAF V600E -positive cells than in BRAF V600E -negative cells. This phenomenon was not entirely dependent on the MAPK pathway, because MEK inhibition did not fully rescue BRAF-induced NIS repression [8] .
TGF-β has been shown to be overproduced in human tumors [13] . Furthermore, overexpression of TGF-β has been reported in thyroid cancers [16, 17] , and this occurrence can lead to increases in epithelial to mesenchymal transition (EMT), migration, and invasion of tumor cells. TGF-β mediates its activities via Smad, which is a potent repressor of NIS in normal epithelial thyroid cells [15] . Moreover, a previous study demonstrated that TGF-β is overexpressed in the invasive front, whereas NIS is preferentially expressed in the central regions of PTC tumors [18] . This suggests that the negative correlation between TGF-β and NIS occurs locally (inside the tumor).
In this study, TGF-β mRNA expression was higher in large PTC tumors than in smaller PTC tumors. In addition, TGF-β expression was higher in tumors exhibiting lymph node metastasis compared with non-lymph node involvement, suggesting that elevated TGF-β is associated with poor outcome. Indeed, a previous study reported that TGF-β2 is significantly increased in PTC compared to benign thyroid nodules [30] . Upon analysis of the relationship between TGF-β and the BRAF V600E mutation, no significant association was observed. This suggests that the TGF-β/Smad pathway and the BRAF V600E mutation play separate roles in PTC, with aberrant activity pertaining to both causing relatively poorer prognosis. Thus, the concomitant occurrence of the BRAF V600E mutation and elevated TGF-β expression (at both the transcriptional and the protein level) may affect the prognosis of PTC. However, we do not believe that this phenomenon is mediated through the inhibition of NIS expression.
Currently, in order to ascertain the status of thyroid nodules in PTC patients, physicians conduct thyroid ultrasound analyses to determine the size, texture, edge, and echo of associated nodules.
Upon occurrence of suspiciously malignant nodules, needle biopsies guided by ultrasound can be performed to determine whether the nodule is benign or malignant (following microscopy). Concurrently, tests are performed to determine the presence or absence of the BRAF V600E mutation. In view of all of these related factors, we generated a matrix that incorporated 4 variables: patient age, tumor size, BRAF V600E mutation, and TGF-β expression. A ROC curve was subsequently plotted to determine the sensitivity and specificity of the panel in forecasting tumor stage. The corresponding AUC was as high as 0.91. The sensitivity and specificity of the model were 94.74 and 83.61%, respectively. These figures are much higher than those observed for the single index. Thus, from a clinical viewpoint, upon observation of clear pathological indicators following biopsy, patients with BRAF V600E and elevated TGF-β expression, who are aged 45 years or older with non-microcarcinoma, should undergo active surgical treatment subject to consent (non-microcarcinoma refers to tumors that are > 1 cm in diameter; routine thyroid ultrasound examination was performed for each patient by an experienced ultrasound physician in order to assess tumor size).
In 2015, the American Thyroid Association (ATA) published management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer [31] . This publication proposed a dynamic risk stratification strategy that predominantly considers the pathological types and clinical features of the tumor, such as tumor size, lymph node metastasis, and extranodal extension. Even though the BRAF V600E mutation is mentioned in the proposed risk stratification system, it is not considered to be an independent risk index. It should be noted that in addition to BRAF V600E , other markers have been suggested as potential prognostic predictors for thyroid cancer. One of these markers is the telomerase reverse transcriptase (TERT) promoter mutation [32] . Coexistent TERT promoter and BRAF V600E mutations have a synergistic effect on clinical outcomes in PTC, whereas each mutation alone has only a modest effect. Thus, this study was conducted with the aim of finding a more convenient and accurate assessment system based on our clinical experiences and the ATA guidelines. It should be noted that there are several limitations associated with this study. First, this evaluation system was established following the statistical analysis of 80 clinical cases. The clinical application of the system requires large sample size verification. Second, since this study predominantly compares the correlation between the BRAF gene with NIS and TGF-β, we did not compare the tumor tissue with paracancerous tissues. In addition, even though immunohistochemical analyses permit the detection of expressed protein localization, they are less accurate than Western blot analyses in quantitate evaluations and can be subject to bias. However, despite these limitations, we believe that this matrix can be applied to evaluate thyroid nodules prior to surgery during clinical diagnosis and treatment.
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